{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:37:59Z","timestamp":1793644679566,"version":"4.5.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,10]],"date-time":"2021-03-10T00:00:00Z","timestamp":1615334400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,10]],"date-time":"2021-03-10T00:00:00Z","timestamp":1615334400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002842","name":"Chiang Mai University","doi-asserted-by":"publisher","award":["16\/2563"],"award-info":[{"award-number":["16\/2563"]}],"id":[{"id":"10.13039\/501100002842","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>We compared the efficacy, safety, and acceptability of lurasidone at different doses to establish the dose\u2013response relationships of lurasidone therapeutic and adverse effects in acute schizophrenia. Included trials were 4- to 16-week, fixed-dose, randomized controlled trials of lurasidone in adults with acute schizophrenia. Different doses of lurasidone, other antipsychotics, and placebo were considered as independent treatments. Apart from all-cause dropout rates, four therapeutic and four adverse outcomes were included in the frequentist network meta-analysis (NMA). Lurasidone 160, 120, 80, 40, and 20\u00a0mg\/day were studied in ten trials of 3,366 adults with schizophrenia exacerbation. Lurasidone 160\u00a0mg\/day reduced Positive and Negative Syndrome Scale (PANSS) total scores significantly more than lurasidone 120, 80, 40, and 20\u00a0mg\/day (mean differences\u2009=\u2009\u2212 7.63, \u2212 7.04, \u2212 8.83, and \u2212 12.25, respectively). All-cause dropout rates were significantly lower in participants receiving lurasidone 160\u00a0mg\/day and 80\u00a0mg\/day compared with those taking placebo. The half-maximal effective doses of lurasidone for PANSS total, PANSS positive, and MADRS score reductions were higher than 80\u00a0mg\/day. The confidence of all NMA estimates was low or very low. Lurasidone 160\u00a0mg\/day is currently the most efficacious and acceptable dose for acute schizophrenia. Its maximal effective doses may be higher than 160\u00a0mg\/day.<\/jats:p>","DOI":"10.1038\/s41598-021-84836-z","type":"journal-article","created":{"date-parts":[[2021,3,10]],"date-time":"2021-03-10T06:03:12Z","timestamp":1615356192000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["A network meta-analysis of the dose\u2013response effects of lurasidone on acute schizophrenia"],"prefix":"10.1038","volume":"11","author":[{"given":"Manit","family":"Srisurapanont","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sirijit","family":"Suttajit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surinporn","family":"Likhitsathian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benchalak","family":"Maneeton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narong","family":"Maneeton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,10]]},"reference":[{"key":"84836_CR1","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/S0140-6736(15)01121-6","volume":"388","author":"MJ Owen","year":"2016","unstructured":"Owen, M. J., Sawa, A. & Mortensen, P. B. Schizophrenia. Lancet 388, 86\u201397 (2016).","journal-title":"Lancet"},{"key":"84836_CR2","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S0006-3223(97)00190-X","volume":"42","author":"LA Arvanitis","year":"1997","unstructured":"Arvanitis, L. A. & Miller, B. G. Multiple fixed doses of \u2018Seroquel\u2019 (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol. Psychiatry 42, 233\u2013246 (1997).","journal-title":"Biol. Psychiatry"},{"key":"84836_CR3","doi-asserted-by":"publisher","first-page":"763","DOI":"10.4088\/JCP.v63n0903","volume":"63","author":"JM Kane","year":"2002","unstructured":"Kane, J. M. et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J. Clin. Psychiatry 63, 763\u2013771 (2002).","journal-title":"J. Clin. Psychiatry"},{"key":"84836_CR4","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","volume":"394","author":"M Huhn","year":"2019","unstructured":"Huhn, M. et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet 394, 939\u2013951 (2019).","journal-title":"Lancet"},{"key":"84836_CR5","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.jpsychires.2018.06.005","volume":"103","author":"W Zheng","year":"2018","unstructured":"Zheng, W. et al. Short-term efficacy and tolerability of lurasidone in the treatment of acute schizophrenia: A meta-analysis of randomized controlled trials. J. Psychiatr. Res. 103, 244\u2013251 (2018).","journal-title":"J. Psychiatr. Res."},{"key":"84836_CR6","doi-asserted-by":"publisher","first-page":"e12352","DOI":"10.1111\/appy.12352","volume":"11","author":"T Higuchi","year":"2019","unstructured":"Higuchi, T. et al. Lurasidone in the treatment of schizophrenia: Results of a double-blind, placebo-controlled trial in Asian patients. Asia-Pac. Psychiatry 11, e12352 (2019).","journal-title":"Asia-Pac. Psychiatry"},{"key":"84836_CR7","doi-asserted-by":"publisher","first-page":"e12354","DOI":"10.1111\/appy.12354","volume":"11","author":"T Higuchi","year":"2019","unstructured":"Higuchi, T. et al. Randomized, double-blind, placebo, and risperidone-controlled study of lurasidone in the treatment of schizophrenia: Results of an inconclusive 6-week trial. Asia Pac. Psychiatry 11, e12354 (2019).","journal-title":"Asia Pac. Psychiatry"},{"key":"84836_CR8","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1177\/2045125315606027","volume":"5","author":"SG Potkin","year":"2015","unstructured":"Potkin, S. G., Kimura, T. & Guarino, J. A 6-week, double-blind, placebo- and haloperidol-controlled, phase II study of lurasidone in patients with acute schizophrenia. Ther. Adv. Psychopharmacol. 5, 322\u2013331 (2015).","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"84836_CR9","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.jpsychires.2013.01.020","volume":"47","author":"HA Nasrallah","year":"2013","unstructured":"Nasrallah, H. A. et al. Lurasidone for the treatment of acutely psychotic patients with schizophrenia: A 6-week, randomized, placebo-controlled study. J. Psychiatr. Res. 47, 670\u2013677 (2013).","journal-title":"J. Psychiatr. Res."},{"key":"84836_CR10","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1002\/npr2.12131","volume":"40","author":"T Kishi","year":"2020","unstructured":"Kishi, T., Nosaka, T., Sakuma, K., Okuya, M. & Iwata, N. Efficacy, tolerability, and safety of lurasidone for acute schizophrenia: A systematic review and network meta-analysis of phase 3 trials in Japan. Neuropsychopharmacol. Rep. 40, 314\u2013322 (2020).","journal-title":"Neuropsychopharmacol. Rep."},{"key":"84836_CR11","unstructured":"Sunovion Pharmaceuticals Canada Inc. Pr Latuda: Product monograph. https:\/\/www.sunovion.ca\/monographs\/latuda.pdf. (2020)."},{"key":"84836_CR12","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbaa063","author":"H Takeuchi","year":"2020","unstructured":"Takeuchi, H. et al. Antipsychotic dose in acute schizophrenia: A Meta-analysis. Schizophr. Bull. https:\/\/doi.org\/10.1093\/schbul\/sbaa063 (2020).","journal-title":"Schizophr. Bull."},{"key":"84836_CR13","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1176\/appi.ajp.2019.19010034","volume":"177","author":"S Leucht","year":"2020","unstructured":"Leucht, S. et al. Dose-response meta-analysis of antipsychotic drugs for acute schizophrenia. Am. J. Psychiatry 177, 342\u2013353 (2020).","journal-title":"Am. J. Psychiatry"},{"key":"84836_CR14","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton, B. et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: Checklist and explanations. Ann. Intern. Med. 162, 777\u2013784 (2015).","journal-title":"Ann. Intern. Med."},{"key":"84836_CR15","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1038\/s41386-019-0573-7","volume":"45","author":"H Tani","year":"2020","unstructured":"Tani, H. et al. Factors associated with successful antipsychotic dose reduction in schizophrenia: A systematic review of prospective clinical trials and meta-analysis of randomized controlled trials. Neuropsychopharmacology 45, 887\u2013901 (2020).","journal-title":"Neuropsychopharmacology"},{"key":"84836_CR16","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne, J. A. C. et al. RoB 2: A revised tool for assessing risk of bias in randomised trials. BMJ 366, l4898 (2019).","journal-title":"BMJ"},{"key":"84836_CR17","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/1471-2288-13-35","volume":"13","author":"U Krahn","year":"2013","unstructured":"Krahn, U., Binder, H. & K\u00f6nig, J. A graphical tool for locating inconsistency in network meta-analyses. BMC Med. Res. Methodol. 13, 35 (2013).","journal-title":"BMC Med. Res. Methodol."},{"key":"84836_CR18","doi-asserted-by":"publisher","first-page":"5414","DOI":"10.1002\/sim.6001","volume":"32","author":"J K\u00f6nig","year":"2013","unstructured":"K\u00f6nig, J., Krahn, U. & Binder, H. Visualizing the flow of evidence in network meta-analysis and characterizing mixed treatment comparisons. Stat. Med. 32, 5414\u20135429 (2013).","journal-title":"Stat. Med."},{"key":"84836_CR19","unstructured":"R Core Team. R: A Language and Environment for Statistical Computing. (R Foundation for Statistical Computing, Vienna, 2020)."},{"key":"84836_CR20","unstructured":"RStudio Team. RStudio: Integrated Development Environment for R. (RStudio, Inc., 2020)."},{"key":"84836_CR21","unstructured":"R\u00fccker, G., Krahn, U., K\u00f6nig, J., Efthimiou, O. & Schwarzer, G. Netmeta: Network Meta-Analysis using Frequentist Methods. (2020)."},{"key":"84836_CR22","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger, M., DaveySmith, G., Schneider, M. & Minder, C. Bias in meta-analysis detected by a simple, graphical test. BMJ 315, 629\u2013634 (1997).","journal-title":"BMJ"},{"key":"84836_CR23","unstructured":"Higgins, J. & Green, S. Cochrane Handbook for Systematic Reviews of Interventions. (The Cochrane Collaboration, 2011)."},{"key":"84836_CR24","doi-asserted-by":"publisher","first-page":"e1003082","DOI":"10.1371\/journal.pmed.1003082","volume":"17","author":"A Nikolakopoulou","year":"2020","unstructured":"Nikolakopoulou, A. et al. CINeMA: An approach for assessing confidence in the results of a network meta-analysis. PLoS Med. 17, e1003082 (2020).","journal-title":"PLoS Med."},{"key":"84836_CR25","doi-asserted-by":"crossref","first-page":"e1080","DOI":"10.1002\/cl2.1080","volume":"16","author":"T Papakonstantinou","year":"2020","unstructured":"Papakonstantinou, T., Nikolakopoulou, A., Higgins, J. P. T., Egger, M. & Salanti, G. CINeMA: Software for semiautomated assessment of the confidence in the results of network meta-analysis. Campbell Syst. Rev. 16, e1080 (2020).","journal-title":"Campbell Syst. Rev."},{"key":"84836_CR26","doi-asserted-by":"publisher","first-page":"14701","DOI":"10.1038\/srep14701","volume":"5","author":"GY Di Veroli","year":"2015","unstructured":"Di Veroli, G. Y. et al. An automated fitting procedure and software for dose\u2013response curves with multiphasic features. Sci. Rep. 5, 14701 (2015).","journal-title":"Sci. Rep."},{"key":"84836_CR27","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1111\/pcn.12965","volume":"74","author":"Y Feng","year":"2020","unstructured":"Feng, Y. et al. Randomized, double-blind, 6-week non-inferiority study of lurasidone and risperidone for the treatment of schizophrenia. Psychiatry Clin. Neurosci. 74, 336\u2013343 (2020).","journal-title":"Psychiatry Clin. Neurosci."},{"key":"84836_CR28","doi-asserted-by":"publisher","first-page":"170","DOI":"10.4088\/JCP.12m07992","volume":"74","author":"JP McEvoy","year":"2013","unstructured":"McEvoy, J. P. et al. Effectiveness of lurasidone in patients with schizophrenia or schizoaffective disorder switched from other antipsychotics: A randomized, 6-week, open-label study. J. Clin. Psychiatry 74, 170\u2013179 (2013).","journal-title":"J. Clin. Psychiatry"},{"key":"84836_CR29","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.schres.2011.04.008","volume":"132","author":"SG Potkin","year":"2011","unstructured":"Potkin, S. G., Ogasa, M., Cucchiaro, J. & Loebel, A. Double-blind comparison of the safety and efficacy of lurasidone and ziprasidone in clinically stable outpatients with schizophrenia or schizoaffective disorder. Schizophr. Res. 132, 101\u2013107 (2011).","journal-title":"Schizophr. Res."},{"key":"84836_CR30","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1089\/cap.2016.0189","volume":"27","author":"R Goldman","year":"2017","unstructured":"Goldman, R., Loebel, A., Cucchiaro, J., Deng, L. & Findling, R. L. Efficacy and safety of lurasidone in adolescents with schizophrenia: a 6-week, randomized placebo-controlled study. J. Child Adolesc. Psychopharmacol. 27, 516\u2013525 (2017).","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"84836_CR31","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1097\/JCP.0000000000001205","volume":"40","author":"HY Meltzer","year":"2020","unstructured":"Meltzer, H. Y., Share, D. B., Jayathilake, K., Salomon, R. M. & Lee, M. A. Lurasidone improves psychopathology and cognition in treatment-resistant schizophrenia. J. Clin. Psychopharmacol. 40, 240\u2013249 (2020).","journal-title":"J. Clin. Psychopharmacol."},{"key":"84836_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jpsychires.2019.02.007","volume":"112","author":"M Jena","year":"2019","unstructured":"Jena, M. et al. Effect of lurasidone vs olanzapine on neurotrophic biomarkers in unmedicated schizophrenia: A randomized controlled trial. J. Psychiatr. Res. 112, 1\u20136 (2019).","journal-title":"J. Psychiatr. Res."},{"key":"84836_CR33","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.4088\/JCP.16m10698","volume":"77","author":"A Loebel","year":"2016","unstructured":"Loebel, A. et al. Lurasidone dose escalation in early nonresponding patients with schizophrenia: A randomized, placebo-controlled study. J. Clin. Psychiatry 77, 1672\u20131680 (2016).","journal-title":"J. Clin. Psychiatry"},{"key":"84836_CR34","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.schres.2013.01.009","volume":"145","author":"A Loebel","year":"2013","unstructured":"Loebel, A. et al. Efficacy and safety of lurasidone 80 mg\/day and 160 mg\/day in the treatment of schizophrenia: A randomized, double-blind, placebo- and active-controlled trial. Schizophr. Res. 145, 101\u2013109 (2013).","journal-title":"Schizophr. Res."},{"key":"84836_CR35","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1176\/appi.ajp.2011.10060907","volume":"168","author":"H Meltzer","year":"2011","unstructured":"Meltzer, H. et al. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study. Am. J. Psychiatry 168, 957\u2013967 (2011).","journal-title":"Am. J. Psychiatry"},{"key":"84836_CR36","doi-asserted-by":"publisher","first-page":"829","DOI":"10.4088\/JCP.08m04905","volume":"70","author":"M Nakamura","year":"2009","unstructured":"Nakamura, M. et al. Lurasidone in the treatment of acute schizophrenia: A double-blind, placebo-controlled trial. J. Clin. Psychiatry 70, 829\u2013836 (2009).","journal-title":"J. Clin. Psychiatry"},{"key":"84836_CR37","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s00213-012-2838-2","volume":"225","author":"M Ogasa","year":"2013","unstructured":"Ogasa, M., Kimura, T., Nakamura, M. & Guarino, J. Lurasidone in the treatment of schizophrenia: A 6-week, placebo-controlled study. Psychopharmacology 225, 519\u2013530 (2013).","journal-title":"Psychopharmacology"},{"key":"84836_CR38","doi-asserted-by":"publisher","first-page":"526","DOI":"10.4088\/JCP.11m07162","volume":"73","author":"EDA Hermes","year":"2012","unstructured":"Hermes, E. D. A., Sokoloff, D., Stroup, T. S. & Rosenheck, R. A. Minimum clinically important difference in the Positive and Negative Syndrome Scale with data from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE). J. Clin. Psychiatry 73, 526\u2013532 (2012).","journal-title":"J. Clin. Psychiatry"},{"key":"84836_CR39","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1097\/YIC.0b013e32832a8eb2","volume":"24","author":"SA Montgomery","year":"2009","unstructured":"Montgomery, S. A. & M\u00f6ller, H.-J. Is the significant superiority of escitalopram compared with other antidepressants clinically relevant?. Int. Clin. Psychopharmacol. 24, 111\u2013118 (2009).","journal-title":"Int. Clin. Psychopharmacol."},{"key":"84836_CR40","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1056\/NEJMoa051688","volume":"353","author":"JA Lieberman","year":"2005","unstructured":"Lieberman, J. A. et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 353, 1209\u20131223 (2005).","journal-title":"N. Engl. J. Med."},{"key":"84836_CR41","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s12874-016-0189-0","volume":"16","author":"A Crippa","year":"2016","unstructured":"Crippa, A. & Orsini, N. Dose\u2013response meta-analysis of differences in means. BMC Med. Res. Methodol. 16, 91 (2016).","journal-title":"BMC Med. Res. Methodol."},{"key":"84836_CR42","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1097\/01.jcp.0000117422.05703.ae","volume":"24","author":"JM Davis","year":"2004","unstructured":"Davis, J. M. & Chen, N. Dose response and dose equivalence of antipsychotics. J. Clin. Psychopharmacol. 24, 192\u2013208 (2004).","journal-title":"J. Clin. Psychopharmacol."},{"key":"84836_CR43","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1017\/S109285291300059X","volume":"19","author":"SG Potkin","year":"2014","unstructured":"Potkin, S. G. et al. D2 receptor occupancy following lurasidone treatment in patients with schizophrenia or schizoaffective disorder. CNS Spectr. 19, 176\u2013181 (2014).","journal-title":"CNS Spectr."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-84836-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-84836-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-84836-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,22]],"date-time":"2023-10-22T17:00:44Z","timestamp":1697994044000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-84836-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,10]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["84836"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-84836-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,10]]},"assertion":[{"value":"9 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In the last three years, MS has received speaker\u2019s honoraria from Lundbeck A\/G, Janssen (Thailand), and Sumitomo Dainippon Pharmaceuticals. In the last three years, SS has received speaker\u2019s honoraria from Mitsubishi Tanabe Pharma (Thailand) and Sumitomo Pharmaceuticals (Thailand). The other authors have no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5571"}}